FEBUXOSTAT

Post-LOESM

febuxostat

ANDAORALTABLET
Approved
Jun 2020
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Xanthine Oxidase Inhibitors

Pharmacologic Class:

Xanthine Oxidase Inhibitor

Clinical Trials (5)

NCT05007392Phase 3Completed

A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout

Started Dec 2021
451 enrolled
Gout
NCT04853160N/ACompleted

Drug Use Study of Febuxostat After Recent Changes in the Prescribing Information

Started Aug 2020
24,046 enrolled
GoutCardiovascular Diseases
NCT03316131Phase 2Completed

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Started Oct 2017
36 enrolled
Asymptomatic Hyperuricemia
NCT03118739Phase 2Completed

Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria

Started May 2017
60 enrolled
HyperuricemiaAlbuminuriaType 2 Diabetes
NCT02504320Phase 1Completed

Phase 1, Febuxostat XR Relative Bioavailability Study

Started Aug 2015
78 enrolled
Healthy Volunteers